Randomized trial shows improved glycemic control and weight loss in individuals with type 2 diabetes and obesity, indicating a promising treatment option.
Key Points
This study aimed to evaluate the effects of tirzepatide on glycemic control and weight loss in patients with type 2 diabetes and obesity.
Systematic literature search for studies involving tirzepatide, type 2 diabetes, and obesity.
Assessment of quality and data extraction from relevant studies using a narrative approach.
Tirzepatide significantly reduced hemoglobin A1c and body mass index compared to placebo and other treatments.
Improvements were also seen in blood pressure, lipid profile, and liver function tests.
Tirzepatide was well tolerated with low incidence of hypoglycemia and serious adverse events.